<DOC>
	<DOCNO>NCT00108316</DOCNO>
	<brief_summary>This study design understand biological measurement , platelet respond serotonin ( chemical blood sometimes refer SERT ) , provide information determine `` ideal dose , '' one specifically tailor individual 's chemistry . The biological measurement obtain test blood sample . There approximately 120 control subject expect enrollment .</brief_summary>
	<brief_title>Determinants Antidepressant Outcomes</brief_title>
	<detailed_description>OBJECTIVE : The objective dose-ranging three-arm study fluoxetine study kinetics serotonin transporter platelet relate antidepressant response compare manipulation serotonin platelet measure standard treatment exists . RESEARCH PLAN : The project examine two method dose adjustment selective serotonin reuptake inhibitor ( SSRI ) treatment : The first method emulate current standard clinical practice , i.e. , titrate dosage base upon subject 's current depression symptomatology ( standard treatment arm ) . The second method utilizes measurement Km create dosage tailor individual approach optimum treatment Kapp ( biological treatment arm ) . Additionally , placebo arm control treatment failure high placebo response . This application double-blind , placebo control , randomize , dose range study male female outpatient Major Depressive Disorder . The propose study take place period 12 week recruit 117 subject ( order achieve 90 completers , 30 arm , assume 30 % dropout rate ) five year period diagnose Major Depression accord DSM-IV criterion . Following 1 week screen period safety assessment complete evaluated Km dosage calculate , subject blindly randomize 1:1:1 ratio either standard treatment , biological arm placebo arm . Subjects return clinic week 4 , 8 , 12 rating platelet Km determination . Response measure dosage adjustment make week 4 8 . A final determination response make week 12 . METHODS : Responders identify accord conventional criterion define subject 1 ) 50 % improvement baseline score , measure Hamilton Depression Scale ( HAM-D ) , 2 ) long meet Major Depressive criterion accord DSM-IV ; 3 ) score &lt; 10 HAM-D 17 item &lt; 15 24-item HAM-D . The efficacy measure Hamilton Depression Scale ( HAM-D ) : The seventeen item scale design measure depression level ; Montgomery-Asberg Depression Rating Scale ( MADRS ) : A scale design provide additional subjective information determine depressive symptom ; The Profile Mood States ( POMS ) Cloninger Temperament Character Index ( TCI ) patient rat scale measure feeling personality trait . The safety parameter include physical examination , vital sign , collection adverse event , 12-lead electrocardiogram ( ECG ) clinical laboratory assessment . CLINICAL RELEVANCE : Previous study indicate fluoxetine effective treatment depression . This study design provide additional information concern method determine dose . Potentially , information gain research may provide cost-effective way find effective dose trial error approach generally use .</detailed_description>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>A current episode satisfy DSMIV criterion Major Depressive Disorder ( except control ) . No psychotropic medication previous 2 week baseline ( SSRIs SNRIs previous 3 month ) . A current depression score 20 great 24item Hamilton Depression Scale ( patient ) . Willingness ability give inform consent . Age 18 . Cardiovascular disease ; subject w/ myocardial infarct within past 3 month , heart failure , evidence compromise cardiac function Uncontrolled hypertension : systolic blood pressure &gt; 160 , diastolic &gt; 95 Previously note thyroid disease , unless clinically euthyroid 2 month . Endocrine disease exogenous hormone except HRT postmenopausal woman . Women use effective method birth control ( barrier method , oral contraceptive and/or IUD ) , pregnant lactate woman . Women menometrorrhagia , premenstrual dysphoric disorder ( PMDD ) , premenopausal hysterectomized woman intact ovary , without HRT . Subjects require concomitant psychotropic medication . Psychotropic medication previous 2 week baseline , 3 month SSRIs SNRIs , 4 month depot neuroleptic . Evidence clinically significant gastrointestinal , hepatic , renal , endocrine , ophthalmologic , neurologic , cardiovascular hematological disease include anemia , hemophilia , significant liver disease . History intolerable side effect propose treatment . Patients ever meet DSMIV criterion psychosis , schizophrenia , bipolar disorder , organic brain syndrome primary Axis I major psychiatric disorder major depression . Controls must without past history depression . Patients meet DSMIV criterion substance abuse past 2 month dependence last 6 month , include positive urine drug screen . History priapism Subjects start new psychotherapy program 16 week study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Depressive Disorder</keyword>
	<keyword>DNA</keyword>
	<keyword>Serotonin</keyword>
</DOC>